All
FDA Approves Onivyde as First-Line Treatment of Metastatic Pancreatic Cancer
February 13th 2024The Food and Drug Administration has approved Onivyde with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma, the agency has announced.
Novel Drug Granted FDA Fast Track in Rare Prostate Cancer Subset
February 13th 2024The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).
Phase 2 Trial Assessing Novel TKI Begins in ALK-Positive NSCLC, Solid Tumors
February 12th 2024Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.